1-12 of 12
Alan Lau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Sonja J. Gill, Paul W.G. Wijnhoven, Jacqueline H.L. Fok, Rebecca L. Lloyd, Jonathan Cairns, Joshua Armenia, Jenni Nikkilä, Alan Lau, Christopher J. Bakkenist, Susan M. Galbraith, Conchita Vens, Mark J. O'Connor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (9): 1614–1626.
https://doi.org/10.1158/1535-7163.MCT-20-0502
Published: 01 September 2021
View article titled, Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
Open the PDF for Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development in another window
Journal Articles

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression

Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1670–1682.
https://doi.org/10.1158/1535-7163.MCT-18-0010
Published: 31 July 2018
View article titled, The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <em>In Vitro</em> and <em>In Vivo</em> to Induce Pancreatic Ductal Adenocarcinoma Regression
Open the PDF for The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <em>In Vitro</em> and <em>In Vivo</em> to Induce Pancreatic Ductal Adenocarcinoma Regression in another window
Includes: Supplementary data
Journal Articles

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed F. Ahmad, Gareth Hughes, Victoria Sheridan, Rajesh Odedra, Paul Farrington, Elaine B. Cadogan, Lucy C. Riches, Antonio Garcia-Trinidad, Andrew G. Thomason, Bhavika Patel, Jennifer Vincent, Alan Lau, Kurt G. Pike, Thomas A. Hunt, Amrita Sule, Nicholas C.K. Valerie, Laura Biddlestone-Thorpe, Jenna Kahn, Jason M. Beckta, Nitai Mukhopadhyay, Bernard Barlaam, Sebastien L. Degorce, Jason Kettle, Nicola Colclough, Joanne Wilson, Aaron Smith, Ian P. Barrett, Li Zheng, Tianwei Zhang, Yingchun Wang, Kan Chen, Martin Pass, Stephen T. Durant, Kristoffer Valerie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1637–1647.
https://doi.org/10.1158/1535-7163.MCT-17-0975
Published: 31 July 2018
View article titled, Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Open the PDF for Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice in another window
Includes: Multimedia, Supplementary data
Journal Articles

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae-Yong Kim, Do-Youn Oh, Jeff Brown, Alan Lau, Mark J. O'Connor, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (4): 566–577.
https://doi.org/10.1158/1535-7163.MCT-16-0378
Published: 02 April 2017
View article titled, AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Open the PDF for AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib

Alan Lau, Elaine Brown, Andrew Thomason, Rajesh Odedra, Victoria Sheridan, Elaine Cadogan, Shirlian Xu, Andy Cui, Paul R. Gavine, Mark O'Connor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C60.
https://doi.org/10.1158/1535-7163.TARG-15-C60
Published: 01 December 2015
View article titled, Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib
Journal Articles

Abstract C59: Role of MTH1 (NUTD1) in cancer cell survival

Husam Alwan, Kay Eckersley, Louise Goodwin, Alan Lau, David Jones, Jason Kettle, Willem M. Nissink, Jon Read, James S. Scott, Benjamin J.M. Taylor, Graeme E. Walker, Kevin M. Foote
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C59.
https://doi.org/10.1158/1535-7163.TARG-15-C59
Published: 01 December 2015
View article titled, Abstract C59: Role of MTH1 (NUTD1) in cancer cell survival
Journal Articles

Abstract A41: Exploiting synthetic lethal interactions in the DNA damage response area and beyond in drug discovery

Mark Wappett, Richard Ward, Paul Fisher, James Bradford, Jonathan Dry, Mark O'Connor, Alan Lau, Steve Durant
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): A41.
https://doi.org/10.1158/1535-7163.PMS-A41
Published: 01 May 2014
View article titled, Abstract A41: Exploiting synthetic lethal interactions in the DNA damage response area and beyond in drug discovery
Journal Articles

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 959–967.
https://doi.org/10.1158/1535-7163.MCT-12-0707
Published: 09 June 2013
View article titled, Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, <em>In Vitro</em> and <em>In Vivo</em> in p53 Functional and Dysfunctional Models of Human Cancer
Open the PDF for Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, <em>In Vitro</em> and <em>In Vivo</em> in p53 Functional and Dysfunctional Models of Human Cancer in another window
Journal Articles

Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer

Charlotte Knights, Christine Chresta, Lucy Riches, Ramu Mangena, Tim Avis, Aisling O'Shaughnessy, Louise Unwin, Victoria Dunham, Louise Jones, Aaron Cranston, Jim Carmichael, Niall Martin, Mark O'Connor, Alan Lau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A114.
https://doi.org/10.1158/1535-7163.TARG-09-A114
Published: 10 December 2009
View article titled, Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer
Journal Articles

Abstract A119: A proteomics‐based approach to identify biomarker profiles of homologous recombination deficiency (HRD) in breast cancer cell lines

John E. Prime, Louise Unwin, Jill Hunter, Richard Allum, Janice A. Nickson, Rachel Rowlinson, Sabrina Giavara, Carsten Lueck, Alan Lau, Mark J. O'Connor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A119.
https://doi.org/10.1158/1535-7163.TARG-09-A119
Published: 10 December 2009
View article titled, Abstract A119: A proteomics‐based approach to identify biomarker profiles of homologous recombination deficiency (HRD) in breast cancer cell lines
Journal Articles

Abstract C119: Identification of gene expression biomarkers that predict sensitivity to the PARP inhibitor olaparib

Alan Lau, Jonathan Dry, Chris Harbron, Charlotte Knights, Lucy Riches, Ramu Mangena, Tim Avis, Helen Brown, Sarah Runswick, Simon Dearden, Aisling O'Shaughnessy, Louise Unwin, John E. Prime, Darren Hodgson, James Carmichael, Mark J. O'Connor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C119.
https://doi.org/10.1158/1535-7163.TARG-09-C119
Published: 10 December 2009
View article titled, Abstract C119: Identification of gene expression biomarkers that predict sensitivity to the PARP inhibitor olaparib
Journal Articles

Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib

Xiaoning Guo, Dihan Shen, Wenxiang Cheng, Yu Bai, Xing‐Zhi Ni, Dan‐ping Shen, Shirong Zhang, Liang Xie, Charlotte Knights, Alan Lau, Mark O'Connor, Xiaolu Yin, Anthony Warford, Yi Gu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B42.
https://doi.org/10.1158/1535-7163.TARG-09-B42
Published: 10 December 2009
View article titled, Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib